Regeneron Launches $500M Venture Investment Arm

Regeneron Pharmaceuticals is venturing into the investment domain, allocating up to $500 million for its new venture capital division, Regeneron Ventures. The initiative, led by former company executives Jay Markowitz and Michael Aberman, aims to support a broad range of health-related companies, extending beyond drug development to include devices and technologies. With a promise to embrace risk and champion innovation, Regeneron Ventures will look to foster an ecosystem conducive to the growth of pioneering biotech firms. This move positions Regeneron alongside other pharmaceutical giants that use venture capital efforts to scout for cutting-edge advancements and strategic partnerships within the industry. Despite a recent slowdown in biotech investments, Regeneron is taking a bold step to stimulate progress in science and medicine by drawing on its legacy of success and industry expertise.

To read more, click here.

[Source: Fierce Biotech, April 15th, 2024]